CA2948126A1 - Therapeutic placental compositions, methods of making and methods of use - Google Patents

Therapeutic placental compositions, methods of making and methods of use Download PDF

Info

Publication number: CA2948126A1
Authority: CA; Canada
Prior art keywords: placental; composition; tissue; cells; cryopreserved
Prior art date: 2014-05-07
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA2948126A

Other languages

English (en)

French (fr)

Inventor

Timothy Jansen

Samson Tom

Alla Danilkovitch

Dana Yoo

Jaime Zerhusen

Gabriele Putz TODD

Amy Elizabeth Johnson

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Osiris Therapeutics Inc

Original Assignee

Osiris Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-05-07

Filing date

2014-05-07

Publication date

2015-11-12

2014-05-07 Application filed by Osiris Therapeutics Inc filed Critical Osiris Therapeutics Inc

2015-11-12 Publication of CA2948126A1 publication Critical patent/CA2948126A1/en

Status Abandoned legal-status Critical Current

Links

239000000203 mixture Substances 0.000 title claims abstract description 613
230000003169 placental effect Effects 0.000 title claims abstract description 598
230000001225 therapeutic effect Effects 0.000 title claims abstract description 149
238000000034 method Methods 0.000 title claims abstract description 140
210000004027 cell Anatomy 0.000 claims abstract description 373
210000001519 tissue Anatomy 0.000 claims abstract description 240
210000005059 placental tissue Anatomy 0.000 claims abstract description 214
208000027418 Wounds and injury Diseases 0.000 claims abstract description 152
206010052428 Wound Diseases 0.000 claims abstract description 136
210000001136 chorion Anatomy 0.000 claims abstract description 114
210000002435 tendon Anatomy 0.000 claims abstract description 37
210000002993 trophoblast Anatomy 0.000 claims abstract description 36
210000000988 bone and bone Anatomy 0.000 claims abstract description 29
230000033115 angiogenesis Effects 0.000 claims abstract description 28
210000003041 ligament Anatomy 0.000 claims abstract description 23
230000008774 maternal effect Effects 0.000 claims abstract description 21
230000008439 repair process Effects 0.000 claims abstract description 20
206010061218 Inflammation Diseases 0.000 claims abstract description 18
230000004054 inflammatory process Effects 0.000 claims abstract description 18
208000014674 injury Diseases 0.000 claims abstract description 18
230000006378 damage Effects 0.000 claims abstract description 17
230000036573 scar formation Effects 0.000 claims abstract description 8
238000005138 cryopreservation Methods 0.000 claims description 79
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 71
230000000694 effects Effects 0.000 claims description 64
102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 61
108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 61
210000002744 extracellular matrix Anatomy 0.000 claims description 58
239000006185 dispersion Substances 0.000 claims description 57
230000002163 immunogen Effects 0.000 claims description 53
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 51
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 51
238000001356 surgical procedure Methods 0.000 claims description 44
239000003795 chemical substances by application Substances 0.000 claims description 42
238000010257 thawing Methods 0.000 claims description 37
108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 36
238000007710 freezing Methods 0.000 claims description 36
102000004127 Cytokines Human genes 0.000 claims description 32
108090000695 Cytokines Proteins 0.000 claims description 32
230000008014 freezing Effects 0.000 claims description 30
230000008569 process Effects 0.000 claims description 28
230000007547 defect Effects 0.000 claims description 27
210000002901 mesenchymal stem cell Anatomy 0.000 claims description 26
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 25
230000009467 reduction Effects 0.000 claims description 24
210000002540 macrophage Anatomy 0.000 claims description 23
108091005804 Peptidases Proteins 0.000 claims description 22
210000000601 blood cell Anatomy 0.000 claims description 22
238000004519 manufacturing process Methods 0.000 claims description 22
239000004365 Protease Substances 0.000 claims description 21
102000035195 Peptidases Human genes 0.000 claims description 20
108091006905 Human Serum Albumin Proteins 0.000 claims description 19
102000008100 Human Serum Albumin Human genes 0.000 claims description 19
230000017423 tissue regeneration Effects 0.000 claims description 19
230000029663 wound healing Effects 0.000 claims description 18
239000003963 antioxidant agent Substances 0.000 claims description 16
230000035899 viability Effects 0.000 claims description 16
230000003110 anti-inflammatory effect Effects 0.000 claims description 15
230000012292 cell migration Effects 0.000 claims description 14
238000000265 homogenisation Methods 0.000 claims description 14
210000003491 skin Anatomy 0.000 claims description 14
230000001965 increasing effect Effects 0.000 claims description 13
230000000770 proinflammatory effect Effects 0.000 claims description 13
231100000241 scar Toxicity 0.000 claims description 13
239000000725 suspension Substances 0.000 claims description 13
102000004190 Enzymes Human genes 0.000 claims description 12
108090000790 Enzymes Proteins 0.000 claims description 12
230000004663 cell proliferation Effects 0.000 claims description 12
230000001684 chronic effect Effects 0.000 claims description 11
102000009027 Albumins Human genes 0.000 claims description 10
108010088751 Albumins Proteins 0.000 claims description 10
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 10
229920001436 collagen Polymers 0.000 claims description 10
210000002950 fibroblast Anatomy 0.000 claims description 10
230000001737 promoting effect Effects 0.000 claims description 10
230000004936 stimulating effect Effects 0.000 claims description 10
210000000845 cartilage Anatomy 0.000 claims description 9
235000011187 glycerol Nutrition 0.000 claims description 9
239000003642 reactive oxygen metabolite Substances 0.000 claims description 9
101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims description 8
102000002274 Matrix Metalloproteinases Human genes 0.000 claims description 8
108010000684 Matrix Metalloproteinases Proteins 0.000 claims description 8
102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims description 8
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 8
208000025865 Ulcer Diseases 0.000 claims description 8
230000007423 decrease Effects 0.000 claims description 8
230000002829 reductive effect Effects 0.000 claims description 8
108010067372 Pancreatic elastase Proteins 0.000 claims description 7
102000016387 Pancreatic elastase Human genes 0.000 claims description 7
230000008901 benefit Effects 0.000 claims description 7
230000015572 biosynthetic process Effects 0.000 claims description 7
239000003814 drug Substances 0.000 claims description 7
231100000397 ulcer Toxicity 0.000 claims description 7
108010035532 Collagen Proteins 0.000 claims description 6
102000008186 Collagen Human genes 0.000 claims description 6
208000034693 Laceration Diseases 0.000 claims description 6
230000001154 acute effect Effects 0.000 claims description 6
235000006708 antioxidants Nutrition 0.000 claims description 6
230000002500 effect on skin Effects 0.000 claims description 6
208000032544 Cicatrix Diseases 0.000 claims description 5
239000002202 Polyethylene glycol Substances 0.000 claims description 5
239000003937 drug carrier Substances 0.000 claims description 5
210000002919 epithelial cell Anatomy 0.000 claims description 5
230000028993 immune response Effects 0.000 claims description 5
229920001223 polyethylene glycol Polymers 0.000 claims description 5
230000037387 scars Effects 0.000 claims description 5
206010011985 Decubitus ulcer Diseases 0.000 claims description 4
206010056340 Diabetic ulcer Diseases 0.000 claims description 4
208000004210 Pressure Ulcer Diseases 0.000 claims description 4
239000000654 additive Substances 0.000 claims description 4
239000003242 anti bacterial agent Substances 0.000 claims description 4
238000000338 in vitro Methods 0.000 claims description 4
238000001727 in vivo Methods 0.000 claims description 4
235000013772 propylene glycol Nutrition 0.000 claims description 4
208000030016 Avascular necrosis Diseases 0.000 claims description 3
206010010356 Congenital anomaly Diseases 0.000 claims description 3
229920002307 Dextran Polymers 0.000 claims description 3
206010031264 Osteonecrosis Diseases 0.000 claims description 3
102000007562 Serum Albumin Human genes 0.000 claims description 3
108010071390 Serum Albumin Proteins 0.000 claims description 3
206010040943 Skin Ulcer Diseases 0.000 claims description 3
206010072170 Skin wound Diseases 0.000 claims description 3
239000000853 adhesive Substances 0.000 claims description 3
230000001070 adhesive effect Effects 0.000 claims description 3
235000010443 alginic acid Nutrition 0.000 claims description 3
229920000615 alginic acid Polymers 0.000 claims description 3
229940088710 antibiotic agent Drugs 0.000 claims description 3
230000003078 antioxidant effect Effects 0.000 claims description 3
210000002805 bone matrix Anatomy 0.000 claims description 3
239000000919 ceramic Substances 0.000 claims description 3
239000002131 composite material Substances 0.000 claims description 3
239000003974 emollient agent Substances 0.000 claims description 3
239000003906 humectant Substances 0.000 claims description 3
239000003755 preservative agent Substances 0.000 claims description 3
231100000019 skin ulcer Toxicity 0.000 claims description 3
235000000346 sugar Nutrition 0.000 claims description 3
150000008163 sugars Chemical class 0.000 claims description 3
230000005641 tunneling Effects 0.000 claims description 3
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 2
DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 claims description 2
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 2
GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims description 2
235000014653 Carica parviflora Nutrition 0.000 claims description 2
241000243321 Cnidaria Species 0.000 claims description 2
229920001917 Ficoll Polymers 0.000 claims description 2
229920001612 Hydroxyethyl starch Polymers 0.000 claims description 2
102000004895 Lipoproteins Human genes 0.000 claims description 2
108090001030 Lipoproteins Proteins 0.000 claims description 2
MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 claims description 2
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 claims description 2
229940072056 alginate Drugs 0.000 claims description 2
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 2
150000004676 glycans Chemical class 0.000 claims description 2
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 2
229940050526 hydroxyethylstarch Drugs 0.000 claims description 2
FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 2
239000003410 keratolytic agent Substances 0.000 claims description 2
150000002772 monosaccharides Chemical class 0.000 claims description 2
210000002381 plasma Anatomy 0.000 claims description 2
229920001282 polysaccharide Polymers 0.000 claims description 2
239000005017 polysaccharide Substances 0.000 claims description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 claims description 2
MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims description 2
229920002554 vinyl polymer Polymers 0.000 claims description 2
102100024785 Fibroblast growth factor 2 Human genes 0.000 claims 2
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 2
208000020339 Spinal injury Diseases 0.000 claims 2
230000000996 additive effect Effects 0.000 claims 2
208000021957 Ocular injury Diseases 0.000 claims 1
206010053716 Wound necrosis Diseases 0.000 claims 1
210000001691 amnion Anatomy 0.000 abstract description 46
208000037816 tissue injury Diseases 0.000 abstract description 11
210000003954 umbilical cord Anatomy 0.000 abstract description 7
235000015110 jellies Nutrition 0.000 abstract description 3
239000008274 jelly Substances 0.000 abstract description 3
210000003785 decidua Anatomy 0.000 abstract description 2
230000008929 regeneration Effects 0.000 abstract description 2
238000011069 regeneration method Methods 0.000 abstract description 2
238000005516 engineering process Methods 0.000 description 128
210000002826 placenta Anatomy 0.000 description 52
230000029087 digestion Effects 0.000 description 51
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 48
102000029816 Collagenase Human genes 0.000 description 36
108060005980 Collagenase Proteins 0.000 description 36
229960002424 collagenase Drugs 0.000 description 35
102000003974 Fibroblast growth factor 2 Human genes 0.000 description 34
239000006228 supernatant Substances 0.000 description 33
239000003102 growth factor Substances 0.000 description 32
239000000243 solution Substances 0.000 description 32
238000011282 treatment Methods 0.000 description 31
YRQNKMKHABXEJZ-UVQQGXFZSA-N chembl176323 Chemical compound C1C[C@]2(C)[C@@]3(C)CC(N=C4C[C@]5(C)CCC6[C@]7(C)CC[C@@H]([C@]7(CC[C@]6(C)[C@@]5(C)CC4=N4)C)CCCCCCCC)=C4C[C@]3(C)CCC2[C@]2(C)CC[C@H](CCCCCCCC)[C@]21C YRQNKMKHABXEJZ-UVQQGXFZSA-N 0.000 description 28
239000000047 product Substances 0.000 description 28
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 27
239000011780 sodium chloride Substances 0.000 description 27
230000001413 cellular effect Effects 0.000 description 25
239000010410 layer Substances 0.000 description 25
108060008682 Tumor Necrosis Factor Proteins 0.000 description 24
230000003833 cell viability Effects 0.000 description 23
102000004169 proteins and genes Human genes 0.000 description 20
108090000623 proteins and genes Proteins 0.000 description 20
102100040247 Tumor necrosis factor Human genes 0.000 description 19
210000005152 placental membrane Anatomy 0.000 description 18
239000002158 endotoxin Substances 0.000 description 17
229920006008 lipopolysaccharide Polymers 0.000 description 17
210000004379 membrane Anatomy 0.000 description 17
239000012528 membrane Substances 0.000 description 17
230000035876 healing Effects 0.000 description 16
238000013508 migration Methods 0.000 description 16
108090000385 Fibroblast growth factor 7 Proteins 0.000 description 14
230000005012 migration Effects 0.000 description 14
238000010186 staining Methods 0.000 description 14
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 13
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 13
102000038379 digestive enzymes Human genes 0.000 description 13
108091007734 digestive enzymes Proteins 0.000 description 13
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 13
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 12
239000002577 cryoprotective agent Substances 0.000 description 12
230000012010 growth Effects 0.000 description 12
239000000137 peptide hydrolase inhibitor Substances 0.000 description 12
101800003838 Epidermal growth factor Proteins 0.000 description 11
102100033237 Pro-epidermal growth factor Human genes 0.000 description 11
230000003115 biocidal effect Effects 0.000 description 11
239000000872 buffer Substances 0.000 description 11
229940116977 epidermal growth factor Drugs 0.000 description 11
238000002955 isolation Methods 0.000 description 11
239000008188 pellet Substances 0.000 description 11
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 11
239000013641 positive control Substances 0.000 description 11
238000002965 ELISA Methods 0.000 description 10
229940088598 enzyme Drugs 0.000 description 10
230000002757 inflammatory effect Effects 0.000 description 10
230000002062 proliferating effect Effects 0.000 description 10
230000004044 response Effects 0.000 description 10
230000028327 secretion Effects 0.000 description 10
102000003972 Fibroblast growth factor 7 Human genes 0.000 description 9
102000003745 Hepatocyte Growth Factor Human genes 0.000 description 9
108090000100 Hepatocyte Growth Factor Proteins 0.000 description 9
238000002679 ablation Methods 0.000 description 9
230000002491 angiogenic effect Effects 0.000 description 9
230000009089 cytolysis Effects 0.000 description 9
230000005847 immunogenicity Effects 0.000 description 9
238000011534 incubation Methods 0.000 description 9
-1 laminins Proteins 0.000 description 9
101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 8
241001465754 Metazoa Species 0.000 description 8
102100035194 Placenta growth factor Human genes 0.000 description 8
230000015556 catabolic process Effects 0.000 description 8
238000006731 degradation reaction Methods 0.000 description 8
230000004927 fusion Effects 0.000 description 8
230000005764 inhibitory process Effects 0.000 description 8
230000036961 partial effect Effects 0.000 description 8
238000012545 processing Methods 0.000 description 8
230000000717 retained effect Effects 0.000 description 8
102000002260 Alkaline Phosphatase Human genes 0.000 description 7
108020004774 Alkaline Phosphatase Proteins 0.000 description 7
102000013519 Lipocalin-2 Human genes 0.000 description 7
108010051335 Lipocalin-2 Proteins 0.000 description 7
102100031248 Patatin-like phospholipase domain-containing protein 2 Human genes 0.000 description 7
208000006735 Periostitis Diseases 0.000 description 7
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 7
239000008151 electrolyte solution Substances 0.000 description 7
229940021013 electrolyte solution Drugs 0.000 description 7
238000002474 experimental method Methods 0.000 description 7
238000001943 fluorescence-activated cell sorting Methods 0.000 description 7
230000006870 function Effects 0.000 description 7
238000007799 mixed lymphocyte reaction assay Methods 0.000 description 7
210000003460 periosteum Anatomy 0.000 description 7
108090000102 pigment epithelium-derived factor Proteins 0.000 description 7
238000012360 testing method Methods 0.000 description 7
238000002560 therapeutic procedure Methods 0.000 description 7
102100040896 Growth/differentiation factor 15 Human genes 0.000 description 6
101000893549 Homo sapiens Growth/differentiation factor 15 Proteins 0.000 description 6
206010021143 Hypoxia Diseases 0.000 description 6
102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 6
108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 6
CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 6
238000003556 assay Methods 0.000 description 6
210000004271 bone marrow stromal cell Anatomy 0.000 description 6
239000006285 cell suspension Substances 0.000 description 6
210000002808 connective tissue Anatomy 0.000 description 6
SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 6
230000007717 exclusion Effects 0.000 description 6
210000002865 immune cell Anatomy 0.000 description 6
FVVLHONNBARESJ-NTOWJWGLSA-H magnesium;potassium;trisodium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;acetate;tetrachloride;nonahydrate Chemical compound O.O.O.O.O.O.O.O.O.[Na+].[Na+].[Na+].[Mg+2].[Cl-].[Cl-].[Cl-].[Cl-].[K+].CC([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O FVVLHONNBARESJ-NTOWJWGLSA-H 0.000 description 6
235000019419 proteases Nutrition 0.000 description 6
230000001172 regenerating effect Effects 0.000 description 6
239000000758 substrate Substances 0.000 description 6
102000011690 Adiponectin Human genes 0.000 description 5
108010076365 Adiponectin Proteins 0.000 description 5
238000008157 ELISA kit Methods 0.000 description 5
102100028071 Fibroblast growth factor 7 Human genes 0.000 description 5
206010016654 Fibrosis Diseases 0.000 description 5
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 5
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 5
101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 5
102100037852 Insulin-like growth factor I Human genes 0.000 description 5
102000004058 Leukemia inhibitory factor Human genes 0.000 description 5
108090000581 Leukemia inhibitory factor Proteins 0.000 description 5
108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 5
102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 5
229940124158 Protease/peptidase inhibitor Drugs 0.000 description 5
208000007536 Thrombosis Diseases 0.000 description 5
238000004458 analytical method Methods 0.000 description 5
239000003146 anticoagulant agent Substances 0.000 description 5
229940127219 anticoagulant drug Drugs 0.000 description 5
230000010261 cell growth Effects 0.000 description 5
238000005119 centrifugation Methods 0.000 description 5
238000005520 cutting process Methods 0.000 description 5
230000004069 differentiation Effects 0.000 description 5
239000011536 extraction buffer Substances 0.000 description 5
230000001605 fetal effect Effects 0.000 description 5
230000004761 fibrosis Effects 0.000 description 5
238000009472 formulation Methods 0.000 description 5
230000001146 hypoxic effect Effects 0.000 description 5
208000015181 infectious disease Diseases 0.000 description 5
239000003112 inhibitor Substances 0.000 description 5
239000000463 material Substances 0.000 description 5
238000003860 storage Methods 0.000 description 5
210000002536 stromal cell Anatomy 0.000 description 5
102000003390 tumor necrosis factor Human genes 0.000 description 5
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 4
102100037362 Fibronectin Human genes 0.000 description 4
108010067306 Fibronectins Proteins 0.000 description 4
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
239000004698 Polyethylene Substances 0.000 description 4
208000002847 Surgical Wound Diseases 0.000 description 4
108090000631 Trypsin Proteins 0.000 description 4
102000004142 Trypsin Human genes 0.000 description 4
102100038232 Vascular endothelial growth factor C Human genes 0.000 description 4
239000000969 carrier Substances 0.000 description 4
238000012512 characterization method Methods 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
230000006862 enzymatic digestion Effects 0.000 description 4
239000012530 fluid Substances 0.000 description 4
239000006260 foam Substances 0.000 description 4
210000002683 foot Anatomy 0.000 description 4
239000012634 fragment Substances 0.000 description 4
230000002147 killing effect Effects 0.000 description 4
230000000670 limiting effect Effects 0.000 description 4
239000007788 liquid Substances 0.000 description 4
239000003550 marker Substances 0.000 description 4
239000011159 matrix material Substances 0.000 description 4
239000013642 negative control Substances 0.000 description 4
FSVCQIDHPKZJSO-UHFFFAOYSA-L nitro blue tetrazolium dichloride Chemical compound [Cl-].[Cl-].COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 FSVCQIDHPKZJSO-UHFFFAOYSA-L 0.000 description 4
238000012856 packing Methods 0.000 description 4
230000007170 pathology Effects 0.000 description 4
238000007790 scraping Methods 0.000 description 4
210000000130 stem cell Anatomy 0.000 description 4
239000003826 tablet Substances 0.000 description 4
239000012588 trypsin Substances 0.000 description 4
230000037314 wound repair Effects 0.000 description 4
102100026802 72 kDa type IV collagenase Human genes 0.000 description 3
108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 3
108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 description 3
102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 3
102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 3
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
102100037241 Endoglin Human genes 0.000 description 3
101000881679 Homo sapiens Endoglin Proteins 0.000 description 3
101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 3
101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 3
101000633605 Homo sapiens Thrombospondin-2 Proteins 0.000 description 3
102000000589 Interleukin-1 Human genes 0.000 description 3
108010002352 Interleukin-1 Proteins 0.000 description 3
101000844802 Lacticaseibacillus rhamnosus Teichoic acid D-alanyltransferase Proteins 0.000 description 3
102000005741 Metalloproteases Human genes 0.000 description 3
108010006035 Metalloproteases Proteins 0.000 description 3
102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 3
206010028980 Neoplasm Diseases 0.000 description 3
102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 3
102100029529 Thrombospondin-2 Human genes 0.000 description 3
108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 description 3
102100038234 Vascular endothelial growth factor D Human genes 0.000 description 3
210000002469 basement membrane Anatomy 0.000 description 3
230000009286 beneficial effect Effects 0.000 description 3
210000001185 bone marrow Anatomy 0.000 description 3
229940098773 bovine serum albumin Drugs 0.000 description 3
238000004113 cell culture Methods 0.000 description 3
239000002771 cell marker Substances 0.000 description 3
230000002338 cryopreservative effect Effects 0.000 description 3
108010007093 dispase Proteins 0.000 description 3
229940079593 drug Drugs 0.000 description 3
210000002219 extraembryonic membrane Anatomy 0.000 description 3
239000011521 glass Substances 0.000 description 3
239000001963 growth medium Substances 0.000 description 3
239000007943 implant Substances 0.000 description 3
239000000543 intermediate Substances 0.000 description 3
210000002510 keratinocyte Anatomy 0.000 description 3
210000003127 knee Anatomy 0.000 description 3
230000014759 maintenance of location Effects 0.000 description 3
230000003278 mimic effect Effects 0.000 description 3
210000005036 nerve Anatomy 0.000 description 3
210000000963 osteoblast Anatomy 0.000 description 3
230000002980 postoperative effect Effects 0.000 description 3
238000003498 protein array Methods 0.000 description 3
238000011084 recovery Methods 0.000 description 3
238000007634 remodeling Methods 0.000 description 3
230000000638 stimulation Effects 0.000 description 3
230000001131 transforming effect Effects 0.000 description 3
102100033312 Alpha-2-macroglobulin Human genes 0.000 description 2
102400000345 Angiotensin-2 Human genes 0.000 description 2
101800000733 Angiotensin-2 Proteins 0.000 description 2
108010081589 Becaplermin Proteins 0.000 description 2
108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 description 2
102100022544 Bone morphogenetic protein 7 Human genes 0.000 description 2
210000003771 C cell Anatomy 0.000 description 2
102100024210 CD166 antigen Human genes 0.000 description 2
208000009043 Chemical Burns Diseases 0.000 description 2
108010012236 Chemokines Proteins 0.000 description 2
102000019034 Chemokines Human genes 0.000 description 2
102000000541 Defensins Human genes 0.000 description 2
108010002069 Defensins Proteins 0.000 description 2
241001269524 Dura Species 0.000 description 2
102000016942 Elastin Human genes 0.000 description 2
108010014258 Elastin Proteins 0.000 description 2
101150021185 FGF gene Proteins 0.000 description 2
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 description 2
101000980840 Homo sapiens CD166 antigen Proteins 0.000 description 2
101001081567 Homo sapiens Insulin-like growth factor-binding protein 1 Proteins 0.000 description 2
101000645296 Homo sapiens Metalloproteinase inhibitor 2 Proteins 0.000 description 2
101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 2
102100027636 Insulin-like growth factor-binding protein 1 Human genes 0.000 description 2
208000005230 Leg Ulcer Diseases 0.000 description 2
102100030417 Matrilysin Human genes 0.000 description 2
102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 2
102100026262 Metalloproteinase inhibitor 2 Human genes 0.000 description 2
206010062575 Muscle contracture Diseases 0.000 description 2
102100030411 Neutrophil collagenase Human genes 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
208000002193 Pain Diseases 0.000 description 2
108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 description 2
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
206010042033 Stevens-Johnson syndrome Diseases 0.000 description 2
102100030416 Stromelysin-1 Human genes 0.000 description 2
102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
108700012920 TNF Proteins 0.000 description 2
102000036693 Thrombopoietin Human genes 0.000 description 2
108010041111 Thrombopoietin Proteins 0.000 description 2
108010009583 Transforming Growth Factors Proteins 0.000 description 2
102000009618 Transforming Growth Factors Human genes 0.000 description 2
108010073919 Vascular Endothelial Growth Factor D Proteins 0.000 description 2
238000005299 abrasion Methods 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
230000032683 aging Effects 0.000 description 2
230000000735 allogeneic effect Effects 0.000 description 2
239000002870 angiogenesis inducing agent Substances 0.000 description 2
210000003423 ankle Anatomy 0.000 description 2
230000000844 anti-bacterial effect Effects 0.000 description 2
239000012984 antibiotic solution Substances 0.000 description 2
239000004599 antimicrobial Substances 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
230000004888 barrier function Effects 0.000 description 2
239000011324 bead Substances 0.000 description 2
BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
239000012876 carrier material Substances 0.000 description 2
239000002975 chemoattractant Substances 0.000 description 2
230000002648 chondrogenic effect Effects 0.000 description 2
230000006835 compression Effects 0.000 description 2
238000007906 compression Methods 0.000 description 2
208000006111 contracture Diseases 0.000 description 2
230000000254 damaging effect Effects 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
230000000779 depleting effect Effects 0.000 description 2
238000011033 desalting Methods 0.000 description 2
238000001514 detection method Methods 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
238000007865 diluting Methods 0.000 description 2
238000006471 dimerization reaction Methods 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
238000002224 dissection Methods 0.000 description 2
238000009826 distribution Methods 0.000 description 2
229920002549 elastin Polymers 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
210000002615 epidermis Anatomy 0.000 description 2
210000005081 epithelial layer Anatomy 0.000 description 2
210000000981 epithelium Anatomy 0.000 description 2
210000003743 erythrocyte Anatomy 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
102000036444 extracellular matrix enzymes Human genes 0.000 description 2
108091007167 extracellular matrix enzymes Proteins 0.000 description 2
230000009969 flowable effect Effects 0.000 description 2
239000012595 freezing medium Substances 0.000 description 2
239000000499 gel Substances 0.000 description 2
229920002674 hyaluronan Polymers 0.000 description 2
KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 2
229940099552 hyaluronan Drugs 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
230000004957 immunoregulator effect Effects 0.000 description 2
230000036512 infertility Effects 0.000 description 2
230000004968 inflammatory condition Effects 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
102000028416 insulin-like growth factor binding Human genes 0.000 description 2
108091022911 insulin-like growth factor binding Proteins 0.000 description 2
230000003993 interaction Effects 0.000 description 2
238000002684 laminectomy Methods 0.000 description 2
210000002414 leg Anatomy 0.000 description 2
230000003902 lesion Effects 0.000 description 2
230000007774 longterm Effects 0.000 description 2
210000003141 lower extremity Anatomy 0.000 description 2
210000003716 mesoderm Anatomy 0.000 description 2
230000002503 metabolic effect Effects 0.000 description 2
230000000394 mitotic effect Effects 0.000 description 2
230000035771 neuroregeneration Effects 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
238000005457 optimization Methods 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
230000000278 osteoconductive effect Effects 0.000 description 2
230000002188 osteogenic effect Effects 0.000 description 2
230000004819 osteoinduction Effects 0.000 description 2
230000009984 peri-natal effect Effects 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
210000004623 platelet-rich plasma Anatomy 0.000 description 2
229920001610 polycaprolactone Polymers 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
238000003672 processing method Methods 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
230000011514 reflex Effects 0.000 description 2
238000012552 review Methods 0.000 description 2
210000000513 rotator cuff Anatomy 0.000 description 2
239000002002 slurry Substances 0.000 description 2
230000007480 spreading Effects 0.000 description 2
238000003892 spreading Methods 0.000 description 2
239000012192 staining solution Substances 0.000 description 2
239000011550 stock solution Substances 0.000 description 2
230000002459 sustained effect Effects 0.000 description 2
230000000451 tissue damage Effects 0.000 description 2
231100000827 tissue damage Toxicity 0.000 description 2
210000003371 toe Anatomy 0.000 description 2
230000008733 trauma Effects 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 1
102100022464 5'-nucleotidase Human genes 0.000 description 1
BGWLYQZDNFIFRX-UHFFFAOYSA-N 5-[3-[2-[3-(3,8-diamino-6-phenylphenanthridin-5-ium-5-yl)propylamino]ethylamino]propyl]-6-phenylphenanthridin-5-ium-3,8-diamine;dichloride Chemical compound [Cl-].[Cl-].C=1C(N)=CC=C(C2=CC=C(N)C=C2[N+]=2CCCNCCNCCC[N+]=3C4=CC(N)=CC=C4C4=CC=C(N)C=C4C=3C=3C=CC=CC=3)C=1C=2C1=CC=CC=C1 BGWLYQZDNFIFRX-UHFFFAOYSA-N 0.000 description 1
SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
101710151806 72 kDa type IV collagenase Proteins 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
108010023728 Alloderm Proteins 0.000 description 1
102100034608 Angiopoietin-2 Human genes 0.000 description 1
208000009786 Anophthalmos Diseases 0.000 description 1
101100208237 Bos taurus THBS2 gene Proteins 0.000 description 1
101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
101150013553 CD40 gene Proteins 0.000 description 1
102100025221 CD70 antigen Human genes 0.000 description 1
101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 1
241001146702 Candidatus Entotheonella factor Species 0.000 description 1
208000018380 Chemical injury Diseases 0.000 description 1
229920001661 Chitosan Polymers 0.000 description 1
229920001287 Chondroitin sulfate Polymers 0.000 description 1
108090000317 Chymotrypsin Proteins 0.000 description 1
102100027995 Collagenase 3 Human genes 0.000 description 1
108050005238 Collagenase 3 Proteins 0.000 description 1
206010010996 Corneal degeneration Diseases 0.000 description 1
206010011039 Corneal perforation Diseases 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
102000004237 Decorin Human genes 0.000 description 1
108090000738 Decorin Proteins 0.000 description 1
102000016911 Deoxyribonucleases Human genes 0.000 description 1
108010053770 Deoxyribonucleases Proteins 0.000 description 1
229920000045 Dermatan sulfate Polymers 0.000 description 1
206010014989 Epidermolysis bullosa Diseases 0.000 description 1
102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
206010016717 Fistula Diseases 0.000 description 1
208000003790 Foot Ulcer Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
108060003393 Granulin Proteins 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
229920002971 Heparan sulfate Polymers 0.000 description 1
206010019909 Hernia Diseases 0.000 description 1
101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 1
101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 description 1
101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 1
101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
101001044940 Homo sapiens Insulin-like growth factor-binding protein 2 Proteins 0.000 description 1
101001044927 Homo sapiens Insulin-like growth factor-binding protein 3 Proteins 0.000 description 1
101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 1
101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 description 1
101000990912 Homo sapiens Matrilysin Proteins 0.000 description 1
101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 description 1
101000990908 Homo sapiens Neutrophil collagenase Proteins 0.000 description 1
101000851058 Homo sapiens Neutrophil elastase Proteins 0.000 description 1
101001001487 Homo sapiens Phosphatidylinositol-glycan biosynthesis class F protein Proteins 0.000 description 1
101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 description 1
101000990915 Homo sapiens Stromelysin-1 Proteins 0.000 description 1
101000659879 Homo sapiens Thrombospondin-1 Proteins 0.000 description 1
101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 1
101000955962 Homo sapiens Vacuolar protein sorting-associated protein 51 homolog Proteins 0.000 description 1
101000742596 Homo sapiens Vascular endothelial growth factor C Proteins 0.000 description 1
101000742599 Homo sapiens Vascular endothelial growth factor D Proteins 0.000 description 1
208000035154 Hyperesthesia Diseases 0.000 description 1
206010021531 Impetigo Diseases 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102000004374 Insulin-like growth factor binding protein 3 Human genes 0.000 description 1
108090000965 Insulin-like growth factor binding protein 3 Proteins 0.000 description 1
102000004375 Insulin-like growth factor-binding protein 1 Human genes 0.000 description 1
108090000957 Insulin-like growth factor-binding protein 1 Proteins 0.000 description 1
102100022710 Insulin-like growth factor-binding protein 2 Human genes 0.000 description 1
102100022708 Insulin-like growth factor-binding protein 3 Human genes 0.000 description 1
102100022338 Integrin alpha-M Human genes 0.000 description 1
102100025390 Integrin beta-2 Human genes 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
229940119178 Interleukin 1 receptor antagonist Drugs 0.000 description 1
102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
108090001007 Interleukin-8 Proteins 0.000 description 1
208000003618 Intervertebral Disc Displacement Diseases 0.000 description 1
208000002260 Keloid Diseases 0.000 description 1
229940124091 Keratolytic Drugs 0.000 description 1
JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 1
206010072138 Limbal stem cell deficiency Diseases 0.000 description 1
208000008930 Low Back Pain Diseases 0.000 description 1
108090000855 Matrilysin Proteins 0.000 description 1
108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
206010028391 Musculoskeletal Pain Diseases 0.000 description 1
206010028570 Myelopathy Diseases 0.000 description 1
102000035092 Neutral proteases Human genes 0.000 description 1
108091005507 Neutral proteases Proteins 0.000 description 1
101710118230 Neutrophil collagenase Proteins 0.000 description 1
101710158668 Placental protein Proteins 0.000 description 1
239000004696 Poly ether ether ketone Substances 0.000 description 1
229920000954 Polyglycolide Polymers 0.000 description 1
102000008217 Pregnancy Proteins Human genes 0.000 description 1
201000002154 Pterygium Diseases 0.000 description 1
206010037779 Radiculopathy Diseases 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
206010039580 Scar Diseases 0.000 description 1
208000036488 Scleral thinning Diseases 0.000 description 1
102000012479 Serine Proteases Human genes 0.000 description 1
108010022999 Serine Proteases Proteins 0.000 description 1
206010041591 Spinal osteoarthritis Diseases 0.000 description 1
231100000168 Stevens-Johnson syndrome Toxicity 0.000 description 1
102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 1
101710108790 Stromelysin-1 Proteins 0.000 description 1
102100028848 Stromelysin-2 Human genes 0.000 description 1
101710108792 Stromelysin-2 Proteins 0.000 description 1
229920006328 Styrofoam Polymers 0.000 description 1
230000006044 T cell activation Effects 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
208000002240 Tennis Elbow Diseases 0.000 description 1
206010053615 Thermal burn Diseases 0.000 description 1
108060008245 Thrombospondin Proteins 0.000 description 1
102000002938 Thrombospondin Human genes 0.000 description 1
102100036034 Thrombospondin-1 Human genes 0.000 description 1
102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 1
206010044223 Toxic epidermal necrolysis Diseases 0.000 description 1
231100000087 Toxic epidermal necrolysis Toxicity 0.000 description 1
102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
206010064996 Ulcerative keratitis Diseases 0.000 description 1
210000003815 abdominal wall Anatomy 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
230000003044 adaptive effect Effects 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
210000001789 adipocyte Anatomy 0.000 description 1
230000002293 adipogenic effect Effects 0.000 description 1
210000000577 adipose tissue Anatomy 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
230000004075 alteration Effects 0.000 description 1
210000004381 amniotic fluid Anatomy 0.000 description 1
210000001264 anterior cruciate ligament Anatomy 0.000 description 1
230000001772 anti-angiogenic effect Effects 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
230000002421 anti-septic effect Effects 0.000 description 1
229940064004 antiseptic throat preparations Drugs 0.000 description 1
230000003416 augmentation Effects 0.000 description 1
201000004195 band keratopathy Diseases 0.000 description 1
230000000975 bioactive effect Effects 0.000 description 1
239000005312 bioglass Substances 0.000 description 1
208000002352 blister Diseases 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000018678 bone mineralization Effects 0.000 description 1
230000010478 bone regeneration Effects 0.000 description 1
239000005388 borosilicate glass Substances 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
201000004781 bullous keratopathy Diseases 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000001175 calcium sulphate Substances 0.000 description 1
235000011132 calcium sulphate Nutrition 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
238000013131 cardiovascular procedure Methods 0.000 description 1
230000005779 cell damage Effects 0.000 description 1
239000013592 cell lysate Substances 0.000 description 1
230000033077 cellular process Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
230000035606 childbirth Effects 0.000 description 1
210000001612 chondrocyte Anatomy 0.000 description 1
229940059329 chondroitin sulfate Drugs 0.000 description 1
210000004252 chorionic villi Anatomy 0.000 description 1
229960002376 chymotrypsin Drugs 0.000 description 1
239000000084 colloidal system Substances 0.000 description 1
210000000795 conjunctiva Anatomy 0.000 description 1
201000000787 conjunctival cancer Diseases 0.000 description 1
208000017903 conjunctival tumor Diseases 0.000 description 1
208000021921 corneal disease Diseases 0.000 description 1
238000002316 cosmetic surgery Methods 0.000 description 1
239000006059 cover glass Substances 0.000 description 1
238000002681 cryosurgery Methods 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
230000006837 decompression Effects 0.000 description 1
230000006735 deficit Effects 0.000 description 1
229940119679 deoxyribonucleases Drugs 0.000 description 1
230000008021 deposition Effects 0.000 description 1
238000009795 derivation Methods 0.000 description 1
AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 1
229940051593 dermatan sulfate Drugs 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
KAKKHKRHCKCAGH-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 KAKKHKRHCKCAGH-UHFFFAOYSA-L 0.000 description 1
210000001951 dura mater Anatomy 0.000 description 1
230000008846 dynamic interplay Effects 0.000 description 1
230000013020 embryo development Effects 0.000 description 1
230000002357 endometrial effect Effects 0.000 description 1
210000004696 endometrium Anatomy 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
208000030533 eye disease Diseases 0.000 description 1
210000000744 eyelid Anatomy 0.000 description 1
210000003195 fascia Anatomy 0.000 description 1
210000004700 fetal blood Anatomy 0.000 description 1
210000003754 fetus Anatomy 0.000 description 1
229940126864 fibroblast growth factor Drugs 0.000 description 1
230000003176 fibrotic effect Effects 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012467 final product Substances 0.000 description 1
230000003890 fistula Effects 0.000 description 1
239000007850 fluorescent dye Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000002683 hand surgery Methods 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
230000002962 histologic effect Effects 0.000 description 1
230000013632 homeostatic process Effects 0.000 description 1
102000052502 human ELANE Human genes 0.000 description 1
229910052588 hydroxylapatite Inorganic materials 0.000 description 1
230000007954 hypoxia Effects 0.000 description 1
230000002519 immonomodulatory effect Effects 0.000 description 1
238000002513 implantation Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
COHYTHOBJLSHDF-BUHFOSPRSA-N indigo dye Chemical compound N\1C2=CC=CC=C2C(=O)C/1=C1/C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-BUHFOSPRSA-N 0.000 description 1
COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 1
238000013101 initial test Methods 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
239000003407 interleukin 1 receptor blocking agent Substances 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
210000001117 keloid Anatomy 0.000 description 1
230000001530 keratinolytic effect Effects 0.000 description 1
206010023332 keratitis Diseases 0.000 description 1
206010023365 keratopathy Diseases 0.000 description 1
238000002372 labelling Methods 0.000 description 1
238000000608 laser ablation Methods 0.000 description 1
238000010872 live dead assay kit Methods 0.000 description 1
208000020442 loss of weight Diseases 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
239000012139 lysis buffer Substances 0.000 description 1
238000002803 maceration Methods 0.000 description 1
210000001161 mammalian embryo Anatomy 0.000 description 1
238000005259 measurement Methods 0.000 description 1
238000010297 mechanical methods and process Methods 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
229940126601 medicinal product Drugs 0.000 description 1
239000002609 medium Substances 0.000 description 1
239000003226 mitogen Substances 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
230000000921 morphogenic effect Effects 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
210000000492 nasalseptum Anatomy 0.000 description 1
230000009826 neoplastic cell growth Effects 0.000 description 1
210000000944 nerve tissue Anatomy 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
230000011164 ossification Effects 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
230000009818 osteogenic differentiation Effects 0.000 description 1
210000004663 osteoprogenitor cell Anatomy 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
150000004995 p-toluidines Chemical class 0.000 description 1
206010033675 panniculitis Diseases 0.000 description 1
235000019834 papain Nutrition 0.000 description 1
208000035824 paresthesia Diseases 0.000 description 1
XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
210000003516 pericardium Anatomy 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
238000000053 physical method Methods 0.000 description 1
108010017843 platelet-derived growth factor A Proteins 0.000 description 1
108010000685 platelet-derived growth factor AB Proteins 0.000 description 1
229920001432 poly(L-lactide) Polymers 0.000 description 1
229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
229920002530 polyetherether ketone Polymers 0.000 description 1
210000003429 pore cell Anatomy 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
238000004321 preservation Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000002250 progressing effect Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
238000000746 purification Methods 0.000 description 1
208000009954 pyoderma gangrenosum Diseases 0.000 description 1
150000003254 radicals Chemical class 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
238000002278 reconstructive surgery Methods 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000002271 resection Methods 0.000 description 1
238000002435 rhinoplasty Methods 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000010008 shearing Methods 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
239000002356 single layer Substances 0.000 description 1
210000004872 soft tissue Anatomy 0.000 description 1
239000002904 solvent Substances 0.000 description 1
230000000392 somatic effect Effects 0.000 description 1
238000000527 sonication Methods 0.000 description 1
208000020431 spinal cord injury Diseases 0.000 description 1
208000005801 spondylosis Diseases 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
238000012430 stability testing Methods 0.000 description 1
238000013190 sterility testing Methods 0.000 description 1
239000012536 storage buffer Substances 0.000 description 1
210000000434 stratum corneum Anatomy 0.000 description 1
230000035882 stress Effects 0.000 description 1
239000008261 styrofoam Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
210000004304 subcutaneous tissue Anatomy 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
210000001258 synovial membrane Anatomy 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
239000003104 tissue culture media Substances 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000000472 traumatic effect Effects 0.000 description 1
229940078499 tricalcium phosphate Drugs 0.000 description 1
235000019731 tricalcium phosphate Nutrition 0.000 description 1
229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
210000000251 trophoblastic cell Anatomy 0.000 description 1
230000001573 trophoblastic effect Effects 0.000 description 1
210000003454 tympanic membrane Anatomy 0.000 description 1
230000036269 ulceration Effects 0.000 description 1
230000003827 upregulation Effects 0.000 description 1
230000006711 vascular endothelial growth factor production Effects 0.000 description 1
210000005166 vasculature Anatomy 0.000 description 1
238000005406 washing Methods 0.000 description 1
210000000707 wrist Anatomy 0.000 description 1
210000002517 zygapophyseal joint Anatomy 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Cell Biology (AREA)
Epidemiology (AREA)
Developmental Biology & Embryology (AREA)
Zoology (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Virology (AREA)
Biotechnology (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pregnancy & Childbirth (AREA)
Dermatology (AREA)
Reproductive Health (AREA)
Gastroenterology & Hepatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Surgery (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CA2948126A 2014-05-07 2014-05-07 Therapeutic placental compositions, methods of making and methods of use Abandoned CA2948126A1 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/US2014/037201 WO2015171142A1 (en)	2014-05-07	2014-05-07	Therapeutic placental compositions, methods of making and methods of use

Publications (1)

Publication Number	Publication Date
CA2948126A1 true CA2948126A1 (en)	2015-11-12

Family

ID=54392804

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2948126A Abandoned CA2948126A1 (en)	2014-05-07	2014-05-07	Therapeutic placental compositions, methods of making and methods of use

Country Status (7)

Country	Link
EP (1)	EP3139935A4 (de)
JP (1)	JP2017514876A (de)
KR (1)	KR20160147058A (de)
AU (1)	AU2014393402A1 (de)
CA (1)	CA2948126A1 (de)
SG (1)	SG11201609254YA (de)
WO (1)	WO2015171142A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11207353B2 (en)	2010-02-18	2021-12-28	Osiris Therapeutics, Inc.	Immunocompatible amniotic membrane products

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP7011135B2 (ja) *	2016-02-19	2022-02-10	佳秀工業株式会社	血管内皮増殖因子産生促進剤の製造方法及び発毛剤の製造方法、並びに血管内皮増殖因子産生促進剤及び発毛剤
CN109069867B (zh)	2016-03-14	2022-02-01	无痛疗法股份有限公司	无细胞胎盘制剂
US10960027B2 (en)	2016-03-23	2021-03-30	Mimedx Group, Inc.	Compositions and methods of treatment with amniotic fluid
WO2018039294A1 (en)	2016-08-24	2018-03-01	Arthrex, Inc.	Tissue use for repair of injury
US10960028B2 (en)	2017-02-01	2021-03-30	Plakous Therapeutics, Inc.	Placental tissue compositions
US11511017B2 (en)	2019-03-12	2022-11-29	Arthrex, Inc.	Ligament reconstruction
WO2021003257A1 (en) *	2019-07-01	2021-01-07	Auxocell Laboratories, Inc.	Methods and compositions for collecting and using placental tissue cells and placental blood cells
US20230021803A1 (en) *	2019-11-21	2023-01-26	Bioventus, Llc	Placental tissue particulate compositions and methods of use
WO2021123320A1 (en) *	2019-12-20	2021-06-24	Dr. Kalali Prof. Mostafazadeh Dipl. Ing. Miedl (Kmm) Gesellschaft Bürgerlichen Rechts	A composition and its use for a universal therapy against tumor cells
KR102116954B1 (ko) *	2019-12-26	2020-05-29	주식회사 엠케이바이오텍	태아 유래 줄기세포의 동결 보존 및 동결 건조용 배지 조성물
JP2023522213A (ja) *	2020-04-17	2023-05-29	クラウン・サイエンティフィック・リミテッド・ライアビリティ・カンパニー	再生非ステロイド性抗炎症組成物、その生産方法、及び使用方法
US12453805B2 (en)	2020-09-24	2025-10-28	Everest Medical Innovation GmbH	Cryoprotective compositions, surgical kits, and methods for protection of a surgical site during cryosurgery
US12426594B2 (en)	2020-09-24	2025-09-30	Everest Medical Innovation GmbH	Cryoprotective compositions and methods for protection of a surgical site during cryosurgery
US20240165166A1 (en) *	2020-10-06	2024-05-23	Osiris Therapeutics, Inc.	Primed placental tissue and uses in regenerative medicine
US20240189364A1 (en) *	2021-02-26	2024-06-13	Arugula Sciences Llc	Villi stromal cells compositions and uses thereof
WO2023192484A2 (en) *	2022-04-01	2023-10-05	Bright Cell, Inc.	A mesenchymal stem cells formulation for cosmetic use
US20240226181A1 (en) *	2023-01-11	2024-07-11	Biostem Technologies, Inc.	Human umbilical cord composition for treatment of peyronie's disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP5101778B2 (ja) *	2000-02-11	2012-12-19	ザジェネラルホスピタルコーポレイション	光化学作用による組織接着
US20030187515A1 (en) *	2002-03-26	2003-10-02	Hariri Robert J.	Collagen biofabric and methods of preparing and using the collagen biofabric
ES2564044T3 (es) *	2003-06-27	2016-03-17	DePuy Synthes Products, Inc.	Células posparto derivadas de tejido del cordón umbilical y métodos de preparación y uso de las mismas
EP2271208A1 (de) *	2008-03-27	2011-01-12	Biolife Solutions, Inc.	VERFAHREN, SYSTEM UND GERÄT FÜR DIE HYPOTHERME(N) GEWINNUNG, DIE LAGERUNG, DEN TRANSPORT UND DIE BANKMÄßIGE AUFBEWAHRUNG VON GEBURTSGEWEBE
AR080219A1 (es) *	2010-02-18	2012-03-21	Osiris Therapeutics Inc	Productos de membranas corionicas inmunocompatibles
US8632512B2 (en) *	2010-04-09	2014-01-21	Kci Licensing, Inc.	Apparatuses, methods, and compositions for the treatment and prophylaxis of chronic wounds
US20140106447A1 (en) *	2012-10-12	2014-04-17	Mimedx Group, Inc.	Compositions and methods for recruiting stem cells

2014
- 2014-05-07 SG SG11201609254YA patent/SG11201609254YA/en unknown
- 2014-05-07 EP EP14891336.1A patent/EP3139935A4/de not_active Withdrawn
- 2014-05-07 KR KR1020167034174A patent/KR20160147058A/ko not_active Withdrawn
- 2014-05-07 WO PCT/US2014/037201 patent/WO2015171142A1/en not_active Ceased
- 2014-05-07 JP JP2016566997A patent/JP2017514876A/ja active Pending
- 2014-05-07 CA CA2948126A patent/CA2948126A1/en not_active Abandoned
- 2014-05-07 AU AU2014393402A patent/AU2014393402A1/en not_active Abandoned

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11207353B2 (en)	2010-02-18	2021-12-28	Osiris Therapeutics, Inc.	Immunocompatible amniotic membrane products
US11510947B2 (en)	2010-02-18	2022-11-29	Osiris Therapeutics, Inc.	Methods of manufacture of immunocompatible amniotic membrane products
US11590173B2 (en)	2010-02-18	2023-02-28	Osiris Therapeutics, Inc.	Methods of manufacture of therapeutic products comprising vitalized placental dispersions
US11986498B2 (en)	2010-02-18	2024-05-21	Osiris Therapeutics, Inc.	Therapeutic products comprising vitalized placental dispersions
US12109241B2 (en)	2010-02-18	2024-10-08	Osiris Therapeutics, Inc.	Methods of manufacture of immunocompatible chorionic membrane products
US12318408B2 (en)	2010-02-18	2025-06-03	Osiris Therapeutics, Inc.	Methods of manufacture of therapeutic products comprising vitalized placental dispersions
US12558377B2 (en)	2010-02-18	2026-02-24	Osiris Therapeutics, Inc.	Immunocompatible chorionic membrane products

Also Published As

Publication number	Publication date
KR20160147058A (ko)	2016-12-21
EP3139935A4 (de)	2017-11-15
SG11201609254YA (en)	2016-12-29
AU2014393402A1 (en)	2016-11-24
JP2017514876A (ja)	2017-06-08
EP3139935A1 (de)	2017-03-15
WO2015171142A1 (en)	2015-11-12

Legal Events

Date	Code	Title	Description
2020-11-07	FZDE	Dead	Effective date: 20200831